EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Association Between Biologics and Janus Kinase Inhibitors With Inflammatory Bowel Disease as Paradoxical Reactions: A Real‐World Assessment

Zhi-Qing Zhan, Jia-Xin Li, Ying-Xuan Chen iD, Jing-Yuan Fang

United European Gastroenterology Journal · 2025-05 · 13 (4) · 531-541

DOI: 10.1002/ueg2.12719 ↗

Kurz gefasst

Fachartikel in der Zeitschrift United European Gastroenterology Journal, online erschienen am 16.12.2024. Verfasst von Zhi-Qing Zhan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, NHC Key Laboratory of Digestive Diseases, State Key Laboratory for Oncogenes and Related Genes, School o…. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Inflammatory Bowel Diseases, Biological Products. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Jiaotong University "STAR" plan, National Natural Science Foundation of China, Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective With limited evidence connecting paradoxical inflammatory bowel disease (paradoxical IBD) to the newest biologics and Janus kinase inhibitors, our study aims to investigate the occurrence of paradoxical IBD induced by these agents in treating other immune‐mediated inflammatory diseases (IMIDs). We aim to identify associated risk signals, the primary affected population, and the risk profile changes over time.

Methods

We performed disproportionality analysis to evaluate paradoxical IBD risk signals using data from the FDA Adverse Event Reporting System. Stratification analyses according to IBD subtype, age, gender, and agents' indications were performed. Weibull shape parameter (WSP) test was conducted to assess paradoxical IBD risk changes over time. Linkage disequilibrium score regression and Mendelian Randomization were employed to evaluate genetic correlations and causality between these agents' indications (i.e., non‐IBD IMIDs) and IBD.

Results

This study included 3296 patients reporting 3407 occurrences of paradoxical IBD following using these agents as primary suspects. Among TNF blockers, consistent positive signals for paradoxical IBD were noted: Adalimumab ( n = 1983, ROR [95%CI] = 1.55 [1.47–1.63]), Infliximab ( n = 545, ROR [95%CI] = 2.12 [1.95–2.32]), Certolizumab Pegol ( n = 342, ROR [95%CI] = 1.9 [1.71–2.12]), and Golimumab ( n = 154, ROR [95%CI] = 1.64 [1.4–1.93]). Ustekinumab, an IL‐12 and IL‐23 antagonist, also showed a strong positive signal ( n = 155, ROR [95%CI] = 2.03 [1.73–2.39]). Conversely, Upadacitinib, Tofacitinib (Janus kinase inhibitors), and Risankizumab (IL‐23 antagonist) exhibited insignificant associations with paradoxical IBD. Crohn's disease (CD) is the mainly developing form. WSP analysis identified two temporal patterns of paradoxical IBD: early failure and random failure types. Significant genetic correlations between three IMIDs and IBD were uncovered, with psoriasis specifically found to causally elevate CD risk.

Conclusions

This study identifies paradoxical IBD as a consistent positive signal across multiple IMID agents, predominantly manifesting as CD, potentially aiding in timely detection and therapeutic decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsInflammatory Bowel DiseasesBiological ProductsHumansFemaleMaleAdultMiddle AgedAdverse Drug Reaction Reporting SystemsUnited StatesPiperidinesPyrimidines

Stichwörter der Autor:innen

IBDIMIDsJAK inhibitorsadalimumabanti‐TNFbiological agentscertolizumabimmune‐mediated inflammatory diseasesinfliximabparadoxical effects

Substanzen

Janus Kinase InhibitorsBiological ProductstofacitinibPiperidinesPyrimidines

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, NHC Key Laboratory of Digestive Diseases, State Key Laboratory for Oncogenes and Related Genes, School of Medicine, Shanghai Institute of Digestive Disease, Renji Hospital, S…
  • Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Ying-Xuan Chen

Förderung

  • Shanghai Jiaotong University "STAR" plan
  • National Natural Science Foundation of China
  • Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support

Zitieren

APA

Zhan, Z. Q., Li, J. X., Chen, Y. X., & Fang, J. Y. (2025). Association Between Biologics and Janus Kinase Inhibitors With Inflammatory Bowel Disease as Paradoxical Reactions: A Real‐World Assessment. United European Gastroenterology Journal, 13(4), 531-541. https://doi.org/10.1002/ueg2.12719

Vancouver

Zhan ZQ, Li JX, Chen YX, Fang JY. Association Between Biologics and Janus Kinase Inhibitors With Inflammatory Bowel Disease as Paradoxical Reactions: A Real‐World Assessment. United European Gastroenterology Journal. 2025;13(4):531-541. doi:10.1002/ueg2.12719

BibTeX
@article{Zhan2025,
  author = {Zhan, Zhi-Qing and Li, Jia-Xin and Chen, Ying-Xuan and Fang, Jing-Yuan},
  title = {Association Between Biologics and Janus Kinase Inhibitors With Inflammatory Bowel Disease as Paradoxical Reactions: A Real‐World Assessment},
  journal = {United European Gastroenterology Journal},
  year = {2025},
  volume = {13},
  number = {4},
  pages = {531--541},
  doi = {10.1002/ueg2.12719}
}
Kostenlos starten →